Re: Papeles volátiles (Small caps)
Publicado: Mar Feb 01, 2011 10:13 am
Discovery Labs Provides Expanded Update Regarding its Program for
Surfaxin� U.S. Marketing Authorization
Company to Hold Conference Call to Detail Progress Towards Surfaxin Complete Response
Warrington, PA -- February 1, 2011 -- Discovery Laboratories, Inc. (Nasdaq: DSCO) is
providing an expanded update regarding ongoing efforts to file a Complete Response intended to gain
U.S. Food and Drug Administration (FDA) marketing authorization for Surfaxin� for the prevention of
respiratory distress syndrome (RDS) in premature infants. On January 10, 2011, Discovery Labs
issued a press release reporting that the FDA had recently provided detailed, written direction in
response to an earlier submitted proposal by Discovery Labs relating to its ongoing comprehensive
preclinical program intended to gain Surfaxin approval. Throughout the conduct of the program,
Discovery Labs has been interacting with the FDA and incorporating the FDA's guidance into its
efforts to complete the program and file the Surfaxin Complete Response. The filing of the Complete
Response is currently targeted for early third quarter 2011 and anticipated to lead to a potential
approval early in the first quarter 2012
Surfaxin� U.S. Marketing Authorization
Company to Hold Conference Call to Detail Progress Towards Surfaxin Complete Response
Warrington, PA -- February 1, 2011 -- Discovery Laboratories, Inc. (Nasdaq: DSCO) is
providing an expanded update regarding ongoing efforts to file a Complete Response intended to gain
U.S. Food and Drug Administration (FDA) marketing authorization for Surfaxin� for the prevention of
respiratory distress syndrome (RDS) in premature infants. On January 10, 2011, Discovery Labs
issued a press release reporting that the FDA had recently provided detailed, written direction in
response to an earlier submitted proposal by Discovery Labs relating to its ongoing comprehensive
preclinical program intended to gain Surfaxin approval. Throughout the conduct of the program,
Discovery Labs has been interacting with the FDA and incorporating the FDA's guidance into its
efforts to complete the program and file the Surfaxin Complete Response. The filing of the Complete
Response is currently targeted for early third quarter 2011 and anticipated to lead to a potential
approval early in the first quarter 2012